Tasman Metals Takes a Dive Midday After Ending Merger Negotiations


Galectin Therapeutics Inc. (NASDAQ:GALT), FireEye Inc (NASDAQ:FEYE) and Hansen Medical, Inc. (NASDAQ:HNSN) 6.06% are this Tuesday’s top gainers midday. The losers are Tasman Metals Ltd (NYSEMKT:TAS), International Tower Hill Mines Ltd (NYSEMKT:THM) and Intrexon Corp (NYSE:XON).

Drug Developer Galectin Surges

Surging +6.85%, today’s top midday gainer is Galectin Therapeutics Inc. (NASDAQ:GALT). The drug developer missed the mark with its results release last Tuesday but is apparently making a comeback. Billionaire George Soros initiated a position in the company in Q1.

Network security company FireEye Inc (NASDAQ:FEYE) jumped +6.36% ahead of its lock-up expiration tomorrow, with which 92 million shares are expected to become available. Tiger Global has maintained a position in the company across two quarters.

Top value fund managers are ready for the small cap bear market to be done

InvestorsDuring the bull market, small caps haven't been performing well, but some believe that could be about to change. Breach Inlet Founder and Portfolio Manager Chris Colvin and Gradient Investments President Michael Binger both expect small caps to take off. Q1 2020 hedge fund letters, conferences and more However, not everyone is convinced. BTIG strategist Read More

The share price of Hansen Medical, Inc. (NASDAQ:HNSN), another Soros Q1 buy, surged +6.06% midday. The firm appointed a new CEO at the start of the month and has also experienced a handful of insider purchases. Today, Cowen and Company lowered its target price to $2.50.

Tasman Metals Dips

Tasman Metals Ltd (NYSEMKT:TAS) dipped -8.65% today after agreeing to end merger negotiations with Flinders Resources Limited. George Soros has maintained a 1.6-million share position in the company across several quarters.

Down -6.25% midday today, International Tower Hill Mines Ltd (NYSEMKT:THM) takes the second spot on today’s list of losers. The John Paulsonpick is still up a solid +51.22% in 2014.

Intrexon Corp (NYSE:XON) slipped -6.12%. In the portfolios of billionaires investors David Einhorn and Daniel Loeb, the biotech company experienced a share price surge late last week but has struggled this year and is down -29.24% YTD.